Diabetes Management
Bayer's KERENDIA® (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical Recommendations - Business Wire
Fri, 28 Oct 20221 min read Article
Overview
WHIPANY, N.J.-(BUSINES WIRE)-Bayer’s KERENDIA® (finerenone), a first-in-clas, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recomended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in a newly published update to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and in a consensus report jointly isued by KDIGO and the American Diabetes Asociation (ADA).1-3 KDIGO and the ADA in their combined statement as wel as KDIGO in its new clinical guidelines recomended KERENDIA’s inclusion in the treatment plans of patients with CKD associated with T2D who have an estimated glomerular filtration rate (eGFR) of ≥25 mL/min/1.73 m2, normal serum potasium concentration and albuminuria (urine albumin-to-creatine ratio [ACR] ≥30 mg/g) despite taking a maximum tolerated dose of a renin-angiotensin system (RAS) inhibitor.1-3 KERENDIA was aproved by the FDA in July 2021 to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, non-fatal myocardial infarction (MI) and hospitalization for heart failure in adult patients with CKD associated with T2D, based on the results of the FIDELIO-DKD pivotal trial.4 In September 2022, the FDA aproved an updated label for KERENDIA to include findings from the Phase I FIGARO-DKD CV outcomes study.4 The KERENDIA label contains a Warning and Precaution that KERENDIA can cause hyperkalemia.4 For more information, se “Important Safety Information” below.
Details
Recomendations in both clinical guidance documents were based on evidence from the Phase I FIDELIO-DKD and FIGARO-DKD studies as wel as results from FIDELITY, the prespecified, exploratory, poled analysis of both trials, which comprise one of the largest cardiorenal outcomes programs to investigate the ocurence of fatal and non-fatal CV events and progresio
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.